Ensysce Biosciences Files 8‑K/A; Corrects Series C Preferred Terms

What Happened

• Ensysce Biosciences, Inc. filed an amendment to its Form 8‑K on August 6, 2026 (an 8‑K/A) to report an entry into a material definitive agreement and to furnish related exhibits. The filing states it should be read with the original 8‑K and that, except as noted, no other information was changed.
• The amendment includes a Certificate of Correction to the Certificate of Designation for Ensysce’s Series C Non‑Voting Convertible Preferred Stock and a company press release as exhibits.

Key Details

• Filing date: August 6, 2026 (Form 8‑K/A).
• Item reported: 1.01 — Entry into a Material Definitive Agreement (see original 8‑K for full agreement details).
• Exhibit 3.3: Certificate of Correction to the Certificate of Designation for Series C Non‑Voting Convertible Preferred Stock.
• Exhibit 99.1: Company press release; Exhibit 104: Inline XBRL cover page.

Why It Matters

• A Certificate of Correction can change the legal terms or clarifications for the Series C preferred shares (for example, conversion, liquidation, or other rights). That could affect the rights of preferred holders and potential impacts on capitalization or shareholder equity — investors should review the corrected certificate to understand any changes.
• The amended filing and press release provide the official documentation and the company’s statement; retail investors should read the exhibits and the original 8‑K to get full, specific details before drawing conclusions about financial or ownership impacts.